Genmab and partner Johnson & Johnson will not support the extension of the user application of cancer treatment Darzalex, shows a document draft from the UK National Institute for Health and Clinical Excellence (NICE), which advises England and Wales on medications, reports sector media Pharmatimes.
In the document, NICE grounds its conclusion citing concerns about the long-term effect of using Darzalex in combination with Velcade, Thalidomid and Dexamethason as first-line treatments for bone marrow cancer with patients well suited for stem cell transplantation.
Today, patients are typically treated with the same cocktail of drugs excluding Darzalex. NICE also bases its decision on concerns of cost relative to effect, Pharmatimes writes.
European heath authorities issued approval for Darzalex in the aforementioned combination back in 2020 as an initial treatment of patients for whom stem cell transplantation is deemed appropriate.
Genmab: Janssen dispute cost DKK 146m in H1
Genmab's successful CEO dismisses retirement plans
Analyst: Genmab may upgrade financial guidance based on Darzalex sales figures
More from MedWatch
Lundbeck chairman demands change: "We can't live with this"
Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.
Coloplast could win big on Polish reimbursement changes
The Polish Ministry of Health has increased the reimbursement amount for hydrophilic catheters, which Coloplast supplies. The Danish medtech company calls the new scheme a "breakthrough."
Several positive elements in Eli Lilly Q3 report, says analyst
.jpg)
An analyst at Sydbank thinks that Eli Lilly's third quarter report includes a number of positive elements, and emphasizes that this could also be good news for competitor Novo Nordisk.
Eli Lilly upgrades earnings per share guidance
On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.
Cloud computing saves money and cuts carbon emissions at Novo Nordisk
Integrating cloud solutions has helped with Novo Nordisk's sustainable transition, Danish media reports.
Clinical Trial Manager 
Director of Biostatistics 
GxP QA Compliance Manager for Quality Assurance 
Regulatory Science Specialist 
Clinical Documentation Specialist 
Senior Programmer at Genmab 
Application Manager (GxP Systems) - Zealand Pharma 
Jr. Software Developer, Cardiac Applications – Medical Devices, DK 
Training manager 
VP, Head of CMC Pharmaceutical and Device Development 
QA Specialist wanted 
Medical Director 
KLIFO is looking for a talented and committed Pharmacovigilance Associate based in Denmark 
Head of Engineering, Syntese